AIDS mortality in China drops by almost two thirds since 2002 when country began free treatment program China’s HIV/AIDS-related mortality offers dropped from 39.3 per 100 person-years in 2002 to 14. This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an unbiased news service editorially, is a program of the Kaiser Family members Foundation, a nonpartisan health care policy research company unaffiliated with Kaiser Permanente.ADVENTRX submits NDA for Exelbine to FDA ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a fresh Drug Software to the U.S. Food and Drug Administration for its product applicant ANX-530 , or Exelbine. Our Exelbine submission includes twelve months of site-specific stability data from our meant commercial manufacturer, which fulfills a request communicated to us by the FDA previously this year. Culley, CEO of ADVENTRX. Related StoriesAlnylam presents positive ongoing stage 2 open-label extension data for Patisiran and RevusiranAllergan settles patent litigation with Amneal linked to NAMENDA XR prolonged release capsulesHutchison MediPharma begins sulfatinib Phase I trial in USADVENTRX retains special worldwide privileges to Exelbine, other than in China, Hong Kong, Taiwan and Macau.